Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Artelo Biosciences (Nasdaq: ARTL) has received FDA clearance for its Investigational New Drug (IND) application for ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This clearance allows Artelo to initiate a Phase 1 single ascending dose study for chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved treatment. ART26.12 is being developed as a non-opioid approach to manage painful neuropathies. The company expects Phase 1 trial results in the first half of 2025. Artelo's FABP inhibitor platform has attracted interest from potential partners due to its preclinical efficacy, novel mechanism, and strong patent estate.
- FDA clearance received for ART26.12 IND application
- First-in-human Phase 1 trial initiation enabled
- Addressing unmet medical need in chemotherapy-induced peripheral neuropathy
- Non-opioid approach to pain management
- Strong interest from potential partners due to preclinical efficacy and patent estate
- Phase 1 trial results not expected until first half of 2025
- No guaranteed success in clinical trials or FDA approval
The FDA's clearance of Artelo Biosciences' IND application for ART26.12 is significant in the medical research field, particularly in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a debilitating condition with limited treatment options, making ART26.12's development a potential breakthrough. The compound's mechanism targets Fatty Acid Binding Protein 5 (FABP5), which plays a role in lipid signaling pathways. This novel approach could offer a non-opioid pain management alternative, addressing a critical need in neuropathic pain treatment.
Preclinical findings have showcased efficacy, but translating these results into clinical success is crucial. The progression to Phase 1 trials is an essential step to assess safety and dosage in humans. Stakeholders should monitor early clinical data to gauge the drug's potential. If successful, ART26.12 could disrupt the pain management market by providing a safer, non-opioid option.
Moreover, this milestone may attract interest from potential partners and investors, considering the compound's novel mechanism and strong intellectual property protections. Collaborations could accelerate development timelines and broaden application scopes.
For retail investors, the short-term focus should be on the initiation of clinical trials and subsequent data. Long-term prospects hinge on successful trial phases, regulatory approvals and commercial viability. While promising, the drug development process is fraught with uncertainty, requiring cautious optimism.
FDA clearance for Artelo Biosciences’ ART26.12 IND application is a notable catalyst for the company's stock. Successful progression into clinical trials often injects optimism into the market, potentially driving stock price increases. However, investors need to remain cautious given the inherent risks in early-phase drug development. The focus should be on upcoming milestones, particularly Phase 1 trial results expected in the first half of 2025.
Artelo's collaboration with Worldwide Clinical Trials, an established contract research organization, adds credibility to trial execution. This partnership may mitigate operational risks, but investors should still scrutinize trial progression and data integrity.
The broader financial impact will depend on subsequent trial phases, potential partnerships and market reception to ART26.12. If the drug successfully navigates the clinical landscape, it could significantly boost Artelo's revenues and market position. Conversely, setbacks could negatively impact investor sentiment and stock performance.
Retail investors should weigh the potential high rewards against the high risks intrinsic to the biotech sector. Diversifying investments and not overexposing to single-event risks are prudent strategies.
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment
Phase 1 trial results expected in the first half of 2025
SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” letter for the Company’s Investigational New Drug (IND) application for ART26.12, for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). FDA clearance of the ART26.12 IND application enables the Company to initiate its first-in-human Phase 1 single ascending dose study. Study startup activities have been initiated in collaboration with the internationally known contract research organization Worldwide Clinical Trials.
ART26.12 is the lead compound in the Company’s proprietary Fatty Acid Binding Protein (FABP) platform and the first selective FABP5 inhibitor to enter clinical trials. The FABP5 target is an intracellular protein involved in lipid signaling and represents a promising mechanism of action for drug candidates that can modify the cellular lipidome. ART26.12 is being developed as a non-opioid approach to the management of painful neuropathies. The Company’s FABP inhibitor platform, and ART26.12 in particular, has garnered interest from a range of potential partners due to its preclinical demonstation of efficacy, novel mechanism, and strong patent estate.
“Receiving IND clearance validates our development efforts and underscores the potential impact of ART26.12 to improve patients’ lives,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We look forward to sharing the initial clinical results with ART26.12 next year. As the leading company pursuing FABP inhibiton we are committed to building on the unique, lipid-modulating mechanism of our FABP inhibitor platform to address life-altering pathologies for which there are few, if any, safe and effective pharmaceutical treatments.”
About ART26.12
Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids involved in cellular signaling. FABPs are often overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor program in clinical development, is a potent and selective small molecule inhibitor of FABP5 being developed as an orally delivered, peripherally acting, non-opioid, new chemical entity for cancer patients suffering from chemotherapy- induced peripheral neuropathy. Invented by Distinguished Professor Iwao Ojima working in collaboration with Professor Martin Kaczocha, both at Stony Brook University, the extensive library of FABP inhibitors was exclusively licensed to Artelo with global rights. Preclinical evidence to date suggest FABP inhibition has broad therapeutic promise for the treatment of multiple cancers, painful neuropathies, cancer bone pain, dermatologic conditions and anxiety disorders.
About CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic pain caused by chemotherapy. Some chemotherapies result in CIPN with
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
What is the purpose of Artelo Biosciences' ART26.12 drug candidate?
When did Artelo Biosciences (ARTL) receive FDA clearance for ART26.12's IND application?
What is the mechanism of action for Artelo Biosciences' ART26.12?
When are the Phase 1 trial results for Artelo Biosciences' ART26.12 expected?
